Enzalutamide in Prostate Cancer after Chemotherapy

被引：5
|
作者：
Berruti, Alfredo [1 ]
Generali, Daniele [2 ]
Tampellini, Marco [3 ]
机构：
[1] Univ Brescia, Brescia, Italy
[2] Istituti Ospitalieri, Cremona, Italy
[3] Univ Turin, Orbassano, Italy
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 367卷 / 25期
关键词：
INCREASED SURVIVAL; MIGRAINE;
D O I：
10.1056/NEJMc1212940
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2448 / 2448
页数：1
相关论文
共 50 条
  • [21] Enzalutamide in Biochemically Recurrent Prostate Cancer
    Pollak, Michael
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (01): : 90 - 90
  • [22] Enzalutamide and metastasis risk in prostate cancer
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (08): : E387 - E387
  • [23] Enzalutamide prolongs prostate cancer survival
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2019, 80 (07) : 370 - 370
  • [24] Comparative effectiveness of enzalutamide before and after chemotherapy in patients with metastatic castration-resistant prostate cancer: A meta-analysis.
    Xu, Kevin Y.
    Shameem, Raji
    Wu, Shenhong
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Budget Impact of Enzalutamide for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Bui, Cat N.
    O'Day, Ken
    Flanders, Scott
    Oestreicher, Nina
    Francis, Peter
    Posta, Linda
    Popelar, Breanna
    Tang, Hong
    Balk, Mark
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (02): : 163 - U171
  • [26] Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer
    Matsubara, Nobuaki
    Yamada, Yoko
    Tabata, Ken-ichi
    Satoh, Takefumi
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Kawahara, Takashi
    Uemura, Hiroji
    Yano, Akihiro
    Kawakami, Satoru
    Otsuka, Masafumi
    Fukasawa, Satoshi
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 142 - 148
  • [27] compared with enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real-world data (ACES).
    Das, Prantik
    Price, James
    Jones, Michael
    Martin-Fernandez, Cristina
    Ali, Akram
    Mugunthan, Thangrarajh
    Mallick, Chandrani
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [28] PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival
    K. Rahbar
    M. Boegemann
    A. Yordanova
    M. Eveslage
    M. Schäfers
    M. Essler
    H. Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 12 - 19
  • [29] PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival
    Rahbar, K.
    Boegemann, M.
    Yordanova, A.
    Eveslage, M.
    Schaefers, M.
    Essler, M.
    Ahmadzadehfar, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (01) : 12 - 19
  • [30] Enzalutamide as monotherapy for advanced prostate cancer: why not?
    Dellavedova, Tristan
    Boetto, Marta
    Olmedo, Jose
    Pablo Sarria, Juan
    Nobile, Raul
    Ponzano, Rolando
    Quinteros, Leandro
    Malizia Reynoso, Enzo
    Minuzzi, Federico
    ARCHIVOS ESPANOLES DE UROLOGIA, 2016, 69 (07): : 393 - 397
12345